What we know about a new health data tracking system being announced by White House
The collaboration between the federal government and Big Tech would allow patients to more seamlessly track and share their medical records or data among doctors, hospital systems and health apps, the administration and participating companies say.
More details of the system are expected to be announced during a White House event dubbed 'Making Health Technology Great Again' later Wednesday.
The system would be maintained by the federal government through the Centers for Medicare and Medicaid Services. Patients will need to opt in to have their medical records and data shared, which CMS says will be kept secure.
Once a patient is in the system, their information could be shared across apps or health systems that have joined the initiative. So, for example, the Apple Health app on your iPhone that tracks your daily step count or your sleep could access lab results from your doctor's office. Putting that information together, the Trump administration says, will offer a fuller picture of your health.
The U.S. Department of Health and Human Services says that 60 companies have signed on to work with the system and that they have pledged to 'deliver results to the American people in the first quarter of 2026.'
Patient advocates and ethicists say many may worry about how their health information – something Americans have long carefully guarded – could be used in ways that they don't want or expect.
'There are enormous ethical and legal concerns,' said Lawrence Gostin, a Georgetown University law professor who specializes in public health. 'Patients across America should be very worried that their medical records are going to be used in ways that harm them and their families.'
Also, digital privacy advocates say are skeptical that patients will be able to count on their data being stored securely.
'This scheme is an open door for the further use and monetization of sensitive and personal health information,' said Jeffrey Chester at the Center for Digital Democracy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
23 minutes ago
- Newsweek
California Removes 900,000 People From Health Care Plan
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Hundreds of thousands have been removed from a health care plan in California over the course of two years, according to data from KFF, a nonprofit health policy research and news organization. About 900,000 Americans were disenrolled from Medicaid in the state as part of the unwinding process happening nationwide after Medicaid coverage was expanded following the COVID-19 pandemic. Newsweek has contacted the California Department of Public Health via email for comment. Why It Matters The unwinding process has resulted in significant drops in Medicaid enrollment across the U.S. There is now growing concern about the rising population of those without health insurance and the wider impacts this could have, such as worsening health outcomes, increasing strain on emergency services and rising medical costs. The worry has been amplified by the recent passing of President Donald Trump's One Big Beautiful Bill, in which funding cuts, a focus on "waste, fraud and abuse" and work requirements are in store for Medicaid. Many have voiced concern that the measures will result in millions losing health coverage. File photo: A doctor walks with a young boy through a hospital. File photo: A doctor walks with a young boy through a To Know In California, there were 14,285,643 covered by Medicaid in March 2023, but by March 2025, that number was 13,392,566, KFF data shows. This was because during the pandemic, some states expanded Medicaid coverage under the Affordable Care Act (ACA), causing nationwide enrollment levels to increase. Federal rules forced states to keep most Medicaid enrollees on the program, even if their eligibility status changed, until March 2023, when they were then allowed to start rolling recipients off the program. This marks a change of about 900,000, a decline that was smaller than other highly populated states like Texas, Florida and New York. In March 2025, the number of people with Medicaid coverage in California was still higher than pre-pandemic levels, by 16 percent. The reason why Medicaid coverage is unwinding at different rates in states is because "states approached the process of reviewing the eligibility of their Medicaid beneficiaries with fundamentally different strategies," Michael Sparer, professor and chair of the Department of Health Policy and Management at Columbia University, told Newsweek. He said that Florida and Texas began the review process "as fast as they could and immediately declared ineligible those beneficiaries who did not promptly respond to review notices." "There is clear evidence that many beneficiaries who were still eligible lost coverage simply because they did not timely navigate the administrative hurdles to recertification," he added. Meanwhile, he said that New York and California "were far more deliberate in how they approached the review process, thus the number who've lost their eligibility via this process is far fewer." What People Are Saying Michael Sparer, professor and chair of the Department of Health Policy and Management at Columbia University, told Newsweek: "Medicaid enrollment surged during the pandemic for several reasons, including increased unemployment combined with a requirement that in exchange for additional federal funding, states could not recertify beneficiary eligibility until the "public health emergency" was declared over. Put simply, millions signed up during the pandemic and their eligibility could only be reviewed beginning in the spring 2023. "There is reason to be quite concerned about how this has played out and also what it suggests may happen when Medicaid work requirements, which create their own set of administrative hurdles, are implemented. First, persons who are eligible for coverage should not lose coverage. Bad health outcomes will follow. Second, persons who are no longer Medicaid eligible should be guided to other options, such as subsidized ACA marketplace coverage. Finally, the variation in how states conduct Medicaid eligibility reviews leads to unfortunate inequities." What Happens Next As the unwinding continues, more reductions in enrollment are expected in California and across the country. With millions already having lost health coverage, concerns remain about access to care for low-income individuals and families.
Yahoo
an hour ago
- Yahoo
3 Medical Stocks to Consider as Markets Take a Breather
The broader indexes have cooled off in the last few trading sessions after what was another pleasant month for the stock market in July. While the market has been able to shrug off trade war concerns on the way to a historic rebound, President Trump has officially signed an executive order to hit most of the United States' trading partners with tariff hikes, which ignited a pullback on Friday as July's Jobs Report came in weaker than expected. Considering the benchmark S&P 500 and the tech-centric Nasdaq looked due for a breather after spiking more than +10% in the last three months, investors may be scoping out some defensive positions. That said, these medical sector stocks may continue to provide this defensive safety, as there will always be a constant need for health care. CVS Health Zacks Rank #2 (Buy) CVS Health's CVS transformation into an innovative pharmacy company with integrated offerings across the entire spectrum of pharmacy care is paying off. Thanks to strong earnings, raised guidance, and renewed investor confidence, CVS stock has surged over +30% this year but still trades at just 10X forward earnings and offers a very generous 4.28% annual dividend yield. In addition to sporting a Zacks Rank #2 (Buy), CVS stock currently checks an overall 'A' VGM Zacks Style Scores grade for the combination of Value, Growth, and Momentum. Image Source: Zacks Investment Research Johnson & Johnson Zacks Rank #2 (Buy) Pharmaceutical giant Johnson & Johnson JNJ checks the value box, with a reasonable 15.1X forward earnings multiple and a 3.16% annual dividend yield. Furthermore, investors seemed to have flocked to Johnson & Johnson stock earlier in the year during heightened market volatility, and JNJ is still up +15% in 2025 to top the S&P 500 and Nasdaq's returns of roughly +7%. Although Johnson & Johnson's growth has slowed, steady top and bottom line expansion is still in the forecast, and the medical leader has one of the most diversified business models. Having more than 275 subsidiaries, Johnson & Johnson's pipeline of drugs/treatments covers neuroscience and mental health, oncology, immunology, pulmonary hypertension, cardiovascular, rare, and infectious diseases. Image Source: Zacks Investment Research Tenet Healthcare Zacks Rank #1 (Strong Buy) We'll round out the list with Tenet Healthcare THC, an investor-owned health care services company that owns and operates general hospitals and health care facilities for urban and rural communities in numerous states. Boasting a Zacks Rank #1 (Strong Buy), THC stock is benefiting from a very pleasant trend of positive earnings estimate revisions. With Tenet Healthcare's annual earnings now expected to leap 25% in fiscal 2025 to $14.92 per share, it's noteworthy that these EPS revisions have climbed 17% in the last 60 days from estimates of $12.69 two months ago. Plus, THC is up +25% YTD and trades at 10X forward earnings. Strongly suggesting Tenet Healthcare's impressive stock performance should continue, FY26 EPS is projected to expand another 4% to $15.48, and estimates have spiked 14% in the last 60 days. On top of being a 'feel-good' investment in regard to Tenet Healthcare reaching underserved communities, THC checks the fundamental trading boxes with an 'A' VGM Zacks Style Scores grade. Image Source: Zacks Investment Research Bottom Line Hopefully, the excitement for AI-driven growth will continue to push the broader market higher, but these top medical stocks can provide the defensive safety that investors may need with volatility starting to resurface amid President Trump's tariff hikes and last month's unfavorable jobs report. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Washington Post
2 hours ago
- Washington Post
States sue Trump administration over access to care for transgender youths
A coalition of more than a dozen states sued the Trump administration on Friday over health care for transgender young people, claiming the White House has 'relentlessly, cruelly, and unlawfully targeted transgender individuals' since President Donald Trump took office. The lawsuit, filed in federal court in Massachusetts, seeks to have part of one executive order issued in January declared unconstitutional. The order targets gender-affirming care provided to people under the age of 19, such as puberty blockers, hormone therapy and surgical procedures, which it refers to as 'mutilation.' The lawsuit also asks the court to declare unlawful the Justice Department's targeting of providers of gender-affirming care. The section of the order that is being challenged directs the Justice Department to use laws such as the Food, Drug and Cosmetic Act, those against female genital mutilation, and child custody legislation to carry out the administration's aims. 'It is the policy of the United States that it will not fund, sponsor, promote, assist, or support the so-called 'transition' of a child from one sex to another,' Trump's order says, calling the treatments 'a stain on our Nation's history.' The states of Massachusetts, California, New York, Connecticut, Illinois, Delaware, Hawaii, Maine, Maryland, Michigan, Nevada, New Jersey, New Mexico, Rhode Island and Wisconsin, as well as the District of Columbia and Josh Shapiro in his capacity as Pennsylvania governor, filed suit. The lawsuit, filed against Trump, the Justice Department and Attorney General Pam Bondi, argues that the executive order conflicts with states' remit to regulate and police medicine and violates the 10th Amendment, which protects states' powers, and is in conflict with many state antidiscrimination laws. Nearly every major medical association endorses the availability of gender-affirming care for transgender young people, citing reductions in depression, substance abuse and suicide attempts. 'Empirical evidence has demonstrated that trans and nonbinary gender identities are normal variations of human identity and expression,' the American Medical Association has said. But the issue, and others related to transgender people, has animated conservatives. Trump has said he wants the 'official policy of the United States' to be that there are only two genders and has referred to being transgender as a 'falsehood.' The administration has moved to ban transgender service members from the military, relocate incarcerated transgender women into men's prisons and bar transgender people from using restrooms that align with their gender identity in federal buildings, among a slew of anti-trans measures, many of which have been challenged in court. After the January order, the lawsuit says, the Justice Department began 'intimidating providers into ceasing care through threats of civil and criminal prosecution.' 'These threats have no basis in law,' the complaint says. 'No federal law prohibits, much less criminalizes, the provision or receipt of gender-affirming care for transgender adolescents.' Puberty blockers temporarily inhibit sex hormones, such as estrogen and testosterone, and other hormone therapies introduce them to the body. Gender-affirming surgeries, such as breast reductions for transgender men, are rarely performed on minors. White House spokesperson Taylor Rogers said in an email that 'everyday Americans resoundingly support' the administration's actions. 'The President has the lawful authority to protect America's vulnerable children through executive action, and the Administration looks forward to ultimate victory on this issue,' she added. In June, the Supreme Court upheld a ban on gender-affirming care for minors in Tennessee.
